<DOC>
	<DOCNO>NCT01944189</DOCNO>
	<brief_summary>Despite preventive program , effective case management still cornerstone malaria control . This study strategy towards improve recommendation resource limited country artemether -lumefantrine ( AL ) treatment order maximize public health benefit . This observational population pharmacokinetics study nested comparative bioavailability study.The study intend describe variability lumefantrine blood level among five year old Ugandan child uncomplicated falciparum malaria receive current standard artemether-lumefantrine dose regimen . Findings form basis development rational dosage recommendation . The nested comparative bioavailability study explore effect profile local food intake ( maize porridge plus vegetable oil versus milk ) lumefantrine uptake . As strategy towards improve recommendation resource limited country AL treatment order maximize public health benefit . As secondary objective correlate variability lumefantrine uptake malaria treatment outcome safety profile population . Research hypotheses 1 . The population pharmacokinetic profile lumefantrine among five year old child Uganda uncomplicated falciparum malaria affect demographic factor . 2 . There difference bioavailability lumefantrine artemether-lumefantrine receive maize porridge plus vegetable oil versus milk among five year old Ugandan child treat uncomplicated falciparum malaria .</brief_summary>
	<brief_title>Artemether/ Lumefantrine : A Study Effect Local Food Pharmacokinetics Population Pharmacokinetics</brief_title>
	<detailed_description>This observational study nest comparative bioavailability study among child base Mulago Hospital , Kampala Uganda . It part profile doctoral study project aim improve artemether-lumefantrine drug use among child resource limited setting order maximize public health benefit . It involve initial healthy volunteer study , quantitative analytical study finally pediatric patient study . Artemether-lumefantrine currently first line treatment uncomplicated malaria Uganda several country sub Saharan Africa . Currently recommend dose regimen child , vulnerable population still empirically weight base derivation base mainly clinical experience study do among adult . Yet child physiologically different adult . In particular lumefantrine , long act agent ensure radical cure highly lipophilic , variable oral bioavailability . High variability lumefantrine uptake long half life render liable selection pressure sub-therapeutic concentration prevail long period . Recommended milk high fat diet improve bioavailability may available resource limit setting . In Mwebaza et al . , 2013 , health volunteer crossover bioavailability study precede plan patient study , lumefantrine exposure comparable milk maize porridge plus oil study group . Whereas fast maize porridge group demonstrate similarly much low range lumefantrine exposure relative milk . The greatly improve absorption attribute little fat use fortify maize porridge . We believe finding healthy adult volunteer relevant vulnerable African child treat AL P. falciparum malaria need confirm . Objectives 1 . To describe population pharmacokinetics lumefantrine among five year old child Uganda receive AL uncomplicated falciparum malaria ( Main study ) . The described PPK profile correlate treatment outcome form basis dose recommendation . 2 . To compare effect maize porridge plus vegetable oil versus milk bioavailability lumefantrine among five year old Ugandan child receive artemether- lumefantrine uncomplicated falciparum malaria ( Nested Study ) . This study establish whether possible recommend fortification carbohydrate rich food little fat ( maize porridge plus vegetable oil ) achieve similarly optimal absorption lumefantrine , milk available resource limit set artemether lumefantrine treatment uncomplicated malaria . Mani sub-study ( 1 ) . A single centre open-label prospective non-comparative pharmacokinetic study carry Department Pharmacology &amp; Therapeutics , Makerere University College Health Sciences , Mulago Hospital Complex , Kampala , Uganda . Study include child ( less 5 year , n=70 ) diagnose uncomplicated falciparum malaria destine receive standard fixed-weight-based six-dose regimen artemether-lumefantrine 3 day outpatient basis . A full population pharmacokinetic design employ obtain sparse venous plasma sample participant schedule period 28 day follow period . Each participant provide 1 8 sample 28 day follow period . Venous plasma level lumefantrine ( L ) metabolite desbutyl-lumefantrine ( DL ) determine use liquid chromatography mass spectrometry tandem ( LCMS/MS ) Division Clinical Pharmacology , Department Laboratory Medicine , Karolinska Institute , Stockholm , Sweden . Outcome variables pharmacokinetic ( PK ) exposure parameter L DL . Sparse PK data pool evaluation individual population PK parameter estimate lumefantrine use NONMEM . Impact patient ' explanatory variable PK parameter assess . Secondary outcome include adverse event day 28 treatment outcome . Nested sub-study ( 2 ) , comparative bioavailability study compare lumefantrine bioavailability first oral dose AL among pediatric patient receive standard care . Forty eight 70 five year old child uncomplicated malaria randomize receive AL either milk ( n=24 ) local maize porridge plus oil ( n=24 ) . Venous plasma concentration ( 1 ml , whole blood ) obtain 8 hour ( 0 , 1 , 1.5 , 2 , 3 , 4 , 6 , 8 ) first use intensive pharmacokinetic sampling design . Thereafter 1 8 sparse venous blood sample obtain 28 day follow period contribute PPK study pool . Primary Pharmacokinetic endpoint outcomes exposure parameter first dose , 8 h. Peak concentration ( Cmax ) early exposure ( AUC0-8h ) use relative bioavailability evaluation use confidence interval approach average bioequivalence . Secondary end point day 28 follow lumefantrine PK exposure ( AUC0-28d AUC0-∞ ) day 28 treatment outcome secondary outcome . Correlation overall exposure ( AUC0-28d AUC0-∞ ) clinical parasitological response AL treatment explore .</detailed_description>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<criteria>Inclusion criterion : Diagnosis uncomplicated falciparum malaria Age ≥ 6 month ≤5 year . For nested comparative bioavailability study , age &gt; 1 ≤5 year age , avoid intense blood draw young child Weight ≥5 kg . For nested comparative bioavailability study , restrict evaluation 2 weight/dose group &gt; 5 &lt; 15kg 15 &lt; 25kg Within 10 km radius recruitment site Informed consent parent guardian Willingness adherence study procedure Exclusion criterion : Severe complicate malaria `` Danger sign '' Mixed plasmodial infection Hemoglobin &lt; 5 mg/dl Weight &lt; 5kg Allergy study medication milk Medication know inhibit induce CYP3A4/5 examples ketoconazole , erythromycin , steroid , antidepressant , anticonvulsant , antiretroviral drug . Receipt artemisinin contain compound past 7 day lumefantrine past 28 day</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>lumefantrine pharmacokinetics &amp; bioavailability</keyword>
</DOC>